A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA

The objective of this investigation is to identify the following problems and questions with respect to the safety and efficacy of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s regulation.

1. Unknown adverse reactions, especially serious adverse reactions
2. Incidences of adverse reactions under routine drug uses
3. Factors that may affect the safety of the drug
4. Factors that may affect the efficacy of the drug

This investigation spanned 3 different studies, 0881A-101575 (alias B1801105) NCT00195403, 0881A-102018 (alias B1801112) NCT00195416 and 0881A-102212 (alias B1801113). All studies have been combined into this record.

Primary care clinic, secondary and tertiary medical centers

Inclusion Criteria

Rheumatoid Arthritis

• Adults: Treatment of active rheumatoid arthritis (RA) in adults when the response to disease-modifying antirhematic drugs (DMARDs), including MTX, has been inadequate
• Children: Treatment of active polyarticular-course chronic active rheumatoid arthritis in children aged 4 to 17 years who have had an inadequate response to, or whom have proved intolerant of, MTX

Psoriatic Arthritis

- Active and progressive psoriatic arthritis (PsA) in adults who do not respond adequately to previous DMARDs

Exclusion Criteria

• Patients to whom Enbrel is contraindicated as per the local labeling
• Patients with known hypersensitivity to Enbrel or any component of the product
• Patients with sepsis or risk of sepsis
• Patients with active infections including chronic or localized infections such as tuberculosis. (Treatment of Enbrel should not be initiated.)